Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Ribavirin for HFRS in Korea
NCT00623168Phase 2Withdrawn
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Feb 2008
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribavirin in hemorrhagic fever with renal syndrome (HFRS), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Number of clinical events (oliguria, dialysis requirement, cardiac arrhythmias, severe hemorrhage) at 5 years and Number of mortalities at 5 years. Planned start Feb 2008; status: withdrawn.
02
Drugs
ribavirin
03
Conditions
hemorrhagic fever with renal syndrome (HFRS)
Beyond the preview
Go deeper on NCT00623168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00623168.